Pfizer settles Viagra® patent litigation with Teva
- Details
- Category: Pfizer
Pfizer Inc. announced that it has settled its litigation against Teva Pharmaceuticals, USA Inc., relating to Pfizer's patent covering the use of Viagra® to treat erectile dysfunction (sildenafil citrate 25, 50, and 100 mg tablets), which expires in April 2020 (including pediatric exclusivity).
Lundbeck and Otsuka to co-develop Lu AF20513, an investigational vaccine against Alzheimer's disease
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) have announced that they will further expand their collaboration to include the development of Lu AF20513, an investigational vaccine candidate against Alzheimer's disease.
FDA Advisory Committee votes on investigational medicine metreleptin
- Details
- Category: AstraZeneca
AstraZeneca and Bristol-Myers Squibb Company today announced the US Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) recommends the investigational medicine metreleptin for the treatment of paediatric and adult patients with generalised lipodystrophy (LD).
Multimillion pound investment in UK life sciences research and development
- Details
- Category: UCB
UCB has today announced the successful completion of a £3.29 million investment in new, cutting-edge robotic laboratory equipment and purpose-built technology at its UK immunology research centre of excellence. The investment centres on an automated antibody discovery platform, designed and built especially for UCB by Farnborough based robotic laboratory experts company Peak Analysis & Automation Ltd (PAA).
Pfizer expands clinical trial data access policy and launches data access portal
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) has announced an update of its clinical trial data access policy that will simplify and broaden access to information gathered in Pfizer-sponsored clinical trials. The updated policy builds upon and expands the company's established methods of clinical trial information sharing, including Pfizer's long track record of submitting for publication results from all interventional clinical trials in patients and its pioneering efforts to provide clinical trial results and data to study participants.
Novartis Africa Day highlights company's efforts to expand access to healthcare
- Details
- Category: Novartis
Novartis senior executives have gathered in Basel, Switzerland for the first-ever Novartis Africa Day, to review the company's innovative work in Africa, including growing commercial activity, novel approaches to expand access to high-quality, affordable medicines, local talent development and the company's Malaria Initiative.
Only 29% of people with diabetes report that their doctors ask them for input for their own treatment plans
- Details
- Category: Novo Nordisk
Results from the global Diabetes Attitudes, Wishes and Needs 2 study (DAWN2™) presented today at a symposium during the World Diabetes Congress of the International Diabetes Federation (IDF), show that only 29% of people with diabetes report that their healthcare team ask for their input when making their treatment plans.
More Pharma News ...
- New study showed significant reduction in blood glucose with Linagliptin alone and in combination with metformin
- Pfizer acquires Polocard, Poland's leading over-the-counter heart attack prevention brand
- Novartis Foundation launches new leprosy strategy at symposium on disease elimination
- GSK responds to FDA decision on Avandia (rosiglitazone)
- Novartis highlights growth prospects driven by significant R&D pipeline progress and the expected increase in blockbuster treatments
- H5N1 vaccine approved by the U.S. FDA as pandemic influenza preparedness measure
- Pfizer and GSK to initiate study of novel combination therapy in patients with melanoma